Catalog No.
Product Name
Application
Product Information
Citations
-
GCGR Modulator
GLP-1R modulator C16 functions as an allosteric modulator by enhancing the binding affinity of GLP-1 to the GLP-1 receptor (GLP-1R) through a transmembrane site, exhibiting an EC50 of 8.43 ± 3.82 μM. This compound is significant for research on glucose homeostasis and diabetes, enabling studies on GLP-1R signaling pathways and therapeutic applications for metabolic disorders. Its modulation potential aids in understanding GLP-1R pharmacology and its implications in drug development. -
GLP-1R/GCGR Agonist
Pemvidutide is a dual agonist of GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR), exhibiting significant effectiveness in promoting weight loss and reducing liver fat as well as serum lipids. It is primarily utilized in research focusing on non-alcoholic steatohepatitis (NASH) and obesity, making it a valuable tool for understanding metabolic disorders and developing therapeutic strategies. -
GLP-1R Modulator
GPCR modulator-1 is a negative allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R). This compound demonstrates key biological activity by modulating receptor signaling, making it valuable for investigating the role of GLP-1R in type 2 diabetes research. GPCR modulator-1 can facilitate studies aimed at understanding metabolic processes and potential therapeutic interventions for diabetes-related complications. -
GLP-1R Agonist
GLP-1R Agonist 4 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), which is crucial for glucose homeostasis and insulin secretion. As a GLP-1R agonist, it mimics the effects of endogenous GLP-1, promoting insulin release in response to elevated blood glucose levels. This compound has significant potential for research applications in diabetes management, particularly in elucidating the mechanisms of GLP-1 signaling and its therapeutic implications. -
GLP-2 Receptor Agonist
Elsiglutide is a selective GLP-2 receptor agonist that functions as a GLP-2 analogue. It promotes intestinal cell proliferation and decreases apoptosis, demonstrating utility in gastrointestinal research. Additionally, Elsiglutide has been shown to mitigate diarrhea induced by Lapatinib in preclinical rodent models, making it a potential candidate for studies focused on enhancing gut health and managing drug side effects. -
GLP-1 Receptor Antagonist
Exendin (5-39) is a selective glucagon-like peptide 1 (GLP-1) receptor antagonist. This compound has been shown to effectively ameliorate memory impairment in β-amyloid protein-treated rodents, making it a valuable tool for studying cognitive decline and neurodegenerative diseases. Its ability to modulate GLP-1 signaling pathways positions Exendin (5-39) as a useful reagent in research focused on metabolic disorders and brain function. -
GLP-1/Gastrine Agonist
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, demonstrating significant potential in improving glycemic control. This compound has been shown to effectively increase β-cell mass, promote β-cell proliferation, and enhance pancreatic islet function. ZP3022 is a valuable tool for research in anti-diabetic therapies and the exploration of metabolic regulation. -
GLP-1R Agonist
GLP-1R agonist 9 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), demonstrating EC50 values of 1.1 nM and 11 nM in CHO GLP-1R Clone H6 and CHO GLP-1R Clone C6, respectively. This compound exhibits significant biological activity in stimulating insulin secretion, making it a valuable tool in diabetes research. Its efficacy in modulating GLP-1R offers potential applications in studying metabolic disorders and developing therapeutic agents for glucose regulation. -
GLP-1 Receptor Agonist
Cochinchinenin C is a nonpolypeptide agonist of the glucagon-like peptide-1 (GLP-1) receptor. This compound exhibits significant biological activity in stimulating insulin secretion and inhibiting glucagon release, making it a valuable tool for diabetes research. Its ability to modulate glucose homeostasis positions Cochinchinenin C as a potential candidate for therapeutic applications in metabolic disorders. -
GLP-1 Receptor Agonist
PF-06954522 citrate is an orally active agonist of the GLP-1 receptor. It plays a significant role in regulating glucose metabolism and promoting insulin secretion, making it a valuable tool for investigating type 2 diabetes mellitus. This compound is particularly relevant for studying the mechanisms underlying glucose homeostasis and potential therapeutic strategies for diabetic conditions. -
LSN3318839 Stereoisomer
(S,R)-LSN3318839 is a stereoisomer of LSN3318839, functioning as a positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R). This compound enhances insulin secretion and exhibits hypoglycemic effects, making it a valuable reagent for research into diabetes and metabolic disorders. Its oral bioactivity positions it as a promising candidate for studies focused on glucose homeostasis andtherapeutic interventions. -
GLP-1R Agonist
DA-302168S is a selective agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 value of 1.32 nM. This compound effectively stimulates insulin secretion and demonstrates hypoglycemic effects while decreasing food intake. DA-302168S primarily targets GLP-1R in primates and humans, with minimal activity observed in rodent and canine models. It is a valuable tool for research in type 2 diabetes and obesity. -
GLP-1 R Agonist
GLP-1 receptor agonist 8 is a potent agonist targeting the glucagon-like peptide-1 receptor (GLP-1 R). This compound demonstrates significant biological activity in promoting insulin secretion and regulating appetite, making it relevant for research applications in diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD). Its pharmacological properties provide valuable insights into metabolic disorders and potential therapeutic strategies. -
GLP-1 Analogue
A8SGLP-1 is an orally active GLP-1 analogue with a serine substitution at position 8. This compound demonstrates key biological activity by effectively reducing blood glucose levels in db/db mouse models while maintaining endogenous GLP-1 function. A8SGLP-1 is designed for research applications in diabetes and metabolic disorder studies, providing valuable insights into GLP-1 receptor modulation and therapeutic potential. -
GLP-1R Agonist
GLP-1R agonist 7 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), characterized by an EC50 of 0.67 µM. This compound plays a significant role in modulating glucose metabolism and is instrumental in diabetes research. Its ability to stimulate insulin secretion and inhibit glucagon release makes it a valuable tool for investigating therapeutic approaches to metabolic disorders. -
Peptide
Exendin-4 (3-39) is a peptide that functions as a selective agonist for the Glucagon-like peptide-1 receptor (GLP-1r). This truncated variant of Exendin-4 is missing the first two amino acids, while retaining its bioactivity. Exendin-4 (3-39) is primarily employed in research exploring metabolic diseases, diabetes, and the hypothalamic-pituitary-adrenal (HPA) axis. Its structural modifications allow for investigations into receptor interactions and signaling pathways related to GLP-1r. -
GLP-1R Agonist
GLP-1R agonist 6 is a potent agonist of the GLP-1 receptor, exhibiting an EC50 of 0.15 nM for human GLP-1R. This compound demonstrates significant biological activity in promoting insulin secretion and glucose homeostasis, making it a valuable tool for research in diabetes and metabolic disorders. Its efficacy in activating GLP-1R positions it as a key reagent for exploring therapeutic strategies targeting glucose regulation and appetite control. -
GCGR Agonist
GLP-1 receptor agonist 3 (compound (R)-4A-1) serves as a potent agonist of the glucagon-like peptide-1 (GLP-1) receptor, making it a valuable tool in diabetes research. This compound exhibits EC50 values of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell line assays, respectively, demonstrating its efficacy in stimulating GLP-1 receptor activity. Its application in studying metabolic disorders and potential therapeutic strategies for diabetes highlights its significance in the field of endocrinology. -
GLP-1R Agonist
GLP-1R agonist 8 is a highly potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of less than 2 nM. This compound is instrumental in stimulating insulin secretion and regulating glucose homeostasis, making it a valuable tool in diabetes research and therapeutic development. Its efficacy in enhancing GLP-1R activity underscores its potential for studying metabolic diseases and investigating the physiological roles of GLP-1 signaling pathways. -
GIP/GLP-1 dual receptor Agonist
GIP/GLP-1 dual receptor agonist-1 is an agonist targeting both GIP and GLP-1 receptors. It exhibits significant biological activity in modulating glucose metabolism and promoting insulin secretion. This reagent is instrumental in research focused on metabolic disorders, particularly non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). -
GLP-1R Agonist
GLP-1R Agonist 1 is a potent agonist targeting the glucagon-like peptide-1 receptor (GLP-1R). Acting as an imidazole derivative, this compound promotes insulin secretion while inhibiting glucagon release, making it a valuable tool in diabetes research. Its mechanism of action supports the investigation of therapies aimed at managing blood glucose levels and enhancing glycemic control. -
GLP-1 Receptor Agonist
TT-OAD2 free base is a non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, exhibiting an EC50 of 5 nM. This compound demonstrates significant potential in the treatment of diabetes by enhancing insulin secretion and regulating blood glucose levels. Its applications extend to research investigating GLP-1 signaling pathways and the development of novel therapeutic strategies for metabolic disorders. -
GLP-1R Agonist
GLP-1R agonist 31 is a potent glucagon-like peptide-1 receptor (GLP-1R) agonist. This compound exhibits significant activity in enhancing insulin secretion and promoting glucose-dependent effects, making it valuable in diabetes research. It can be utilized in studies related to metabolic disorders and the development of GLP-1-based therapies. -
GLP-1R Agonist
GLP-1R Agonist 5 is a highly potent agonist of the GLP-1 receptor, exhibiting an EC50 of less than 10 nM. This compound demonstrates significant biological activity in promoting insulin secretion and aiding in glucose homeostasis. It is a valuable tool for research applications focused on metabolic disorders, diabetes, and related therapeutic targets. -
GCGR Agonist
GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist that serves as an effective activator of the GLP-1 receptor, exhibiting an EC50 of 64.5 nM. This compound plays a significant role in enhancing insulin secretion and promoting glucose homeostasis. GLP-1 receptor agonist 4 is primarily utilized in research focused on diabetes treatment and related metabolic disorders. -
Stable Isotope
GLP-1 receptor agonist 17-d3 is a deuterium-labeled compound that targets the GLP-1 receptor, serving as a critical tool in the study of GLP-1 receptor activation. This isotopically enriched agonist plays a significant role in the investigation of cardiovascular and metabolic diseases, providing insights into GLP-1 signaling pathways and their therapeutic implications. Its unique labeling allows for enhanced tracking and identification in biological assays, facilitating advanced research in the field of metabolic health. -
GLP-1R Agonist
GLP-1R agonist 32 is a potent and selective agonist of the GLP-1 receptor, demonstrating an EC50 of 0.017 nM. Its mechanism involves the stimulation of cAMP production, which enhances insulin secretion, suppresses glucagon release, and slows gastric emptying. This compound holds significant promise for investigating therapeutic strategies in type 2 diabetes, obesity, and associated metabolic disorders. -
GLP-1R Agonist
Danuglipron tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. This compound exhibits significant biological activity in promoting insulin secretion and suppressing glucagon release, making it a valuable tool for research in type 2 diabetes. Its mechanism of action supports investigations into glucose metabolism and potential therapeutic approaches for managing diabetes-related conditions. -
GLP-1R Agonist
Lotiglipron is an orally active GLP-1 receptor agonist that plays a crucial role in enhancing glucose-dependent insulin secretion and reducing appetite. This compound is primarily utilized in research related to Type 2 diabetes mellitus (T2DM) and metabolic disorders, demonstrating significant effects on glycemic control and weight management. Its unique mechanism makes Lotiglipron a valuable tool for studying potential therapeutic strategies in diabetes treatment. -
Semaglutide Intermediate
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is a key intermediate in the synthesis of Semaglutide, a glucagon-like peptide 1 receptor (GLP-1R) agonist. This compound is essential for facilitating the development of therapeutics targeting GLP-1R, which plays a crucial role in glucose metabolism and appetite regulation. Research applications include the study of metabolic disorders and the development of obesity and diabetes treatments. -
GLP-1R Agonist
Aleniglipron is a potent glucagon-like peptide-1 receptor (GLP-1R) agonist that exhibits an EC50 value of less than 0.1 nM in human-derived beta (HDB) cell lines through cAMP stimulation assays. This compound selectively activates the Gαs-cAMP signaling pathway of GLP-1R, avoiding β-arrestin recruitment. Aleniglipron is demonstrated to enhance insulin release, improve glucose clearance, reduce food intake, and promote weight loss. It serves as a valuable tool in research focused on type 2 diabetes and obesity. -
GLP-1 Analog
GLP-1 (7-36), amide, biotin labeled is a biotinylated analog of human Glucagon-Like Peptide 1, specifically comprising the C-terminal region. This compound serves as a valuable tool for studying GLP-1 receptor interactions and signaling pathways. It is commonly utilized in research applications focused on metabolic disorders, diabetes, and obesity, providing insights into peptide hormone functions and their implications in therapeutic development. -
GPCR Agonist
Tryptophan-cholic acid (Trp-CA) serves as an agonist for the orphan G protein-coupled receptor MRGPRE, exhibiting an EC50 of 9.6 μM. This compound facilitates the secretion of glucagon-like peptide GLP-1, improving glucose tolerance in diabetic mouse models. Although Trp-CA is orally effective, its poor absorption and inability to cross the blood-brain barrier limit its systemic application. Its primary research applications focus on understanding mechanisms in type 2 diabetes (T2D) and investigating treatments for insulin secretion and hepatic steatosis associated with high-fat diets. -
GLP-1R PAM
V-0219 is an orally active positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R). This compound enhances GLP-1R signaling, making it a valuable tool for studying therapeutic strategies in obesity-associated diabetes and related metabolic disorders. Its mechanism of action offers potential insights into the modulation of glucose homeostasis and appetite regulation. -
GLP-1R Modulator
LSN3160440 is an allosteric modulator of the GLP-1 receptor (GLP-1R) that enhances protein-protein interactions, effectively functioning as a molecular glue. By stabilizing the binding of inactive GLP-1 (9-36) NH2 to GLP-1R, it facilitates receptor activation and downstream signaling. This compound is valuable in studying metabolic disorders and diabetes-related research, providing insights into GLP-1R modulation and its therapeutic potential. -
Antioxidant Agent
Cinnamtannin A2, a tetrameric procyanidin, functions as a potent antioxidant agent. It has been shown to enhance GLP-1 levels and stimulate insulin secretion in murine models. Additionally, Cinnamtannin A2 upregulates the expression of corticotropin-releasing hormone and demonstrates significant anti-diabetic and nephroprotective effects, making it valuable for research in metabolic and renal health. -
GLP-1 Receptor Agonist
Albiglutide fragment is a GLP-1 receptor agonist that corresponds to a biologically active form of the GLP-1 (7-36) analog. This peptide plays a crucial role in modulating glucose metabolism by stimulating insulin secretion and reducing glycosylated hemoglobin (A1C) levels, making it a valuable tool in type 2 diabetes (T2D) research. Its unique structure, derived from a DPP-4 resistant GLP-1 dimer fused with the human albumin gene, enhances its stability and provides insights into long-acting therapeutic options for diabetes management. -
GLP-1 Receptor Agonist
(4S)-GLP-1 receptor agonist 14 is a potent agonist targeting the GLP-1 receptor, exhibiting an EC50 of ≤ 20 nM. This compound is effective in stimulating insulin secretion and has applications in the study of diabetes, obesity, and metabolic disorders. Additionally, it may provide insights into cardiovascular diseases, liver diseases, and nonalcoholic steatohepatitis (NASH), making it a valuable tool for researchers investigating GLP-1 receptor-related pathways. -
GLP-1 Agonist
GLP-1R agonist 10 is a potent GLP-1 receptor agonist, exhibiting an EC50 of 0.051 nM. This compound stimulates insulin secretion in a glucose-dependent manner, thereby enhancing glucose homeostasis. It is primarily utilized in research applications focused on metabolic disorders, diabetes treatment, and the mechanistic study of GLP-1 signaling pathways. -
GLP-1 Agonist
GLP-1 receptor agonist 7 is a highly effective agonist targeting the glucagon-like peptide-1 (GLP-1) receptor. This compound stimulates cAMP production via GLP-1R activation with an EC50 of ≤ 0.2 nM. GLP-1 receptor agonist 7 is valuable for research applications related to metabolic disorders, particularly type 2 diabetes, facilitating the investigation of GLP-1-mediated pathways and potential therapeutic interventions. -
GLP-1 Receptor Agonist
GLP-1 receptor agonist 11 is a selective agonist of the glucagon-like peptide-1 (GLP-1) receptor. This compound demonstrates significant biological activity in stimulating insulin secretion and inhibiting glucagon release, making it a valuable tool in diabetes research. Additionally, GLP-1 receptor agonist 11 may be applied in studies related to non-alcoholic fatty liver disease, offering insights into metabolic regulation and potential therapeutic strategies. -
GLP-1 Antagonist
Exendin(9-39) amide acetate is a potent glucagon-like peptide-1 (GLP-1) antagonist that selectively competes with endogenous GLP-1 for the GLP-1 receptor (GLP-1R). By inhibiting GLP-1 signaling, it counteracts the physiological effects associated with elevated GLP-1 levels. This reagent is particularly valuable for research into postbariatric hypoglycemia (PBH) and other metabolic disorders where GLP-1 modulation is critical. -
GLP-1 Activator
3-Deoxyglucosone is a GLP-1 activator that plays a critical role in the Maillard reaction and the polyol pathway. This reactive intermediate interacts with protein amino groups to produce advanced glycation end products (AGEs), particularly imidazolone, the most specific AGE for 3-Deoxyglucosone. Additionally, it enhances GLP-1 secretion in the presence of low glucose levels, positioning it as a valuable biomarker for diabetes research. -
GLP Receptor Agonist
GLP-1 receptor agonist 14 is a potent agonist of the glucagon-like peptide-1 (GLP-1) receptor. This compound demonstrates significant biological activity in promoting insulin secretion and enhancing glucose-dependent insulin release, making it a valuable tool for research in diabetes and metabolic disorders. Its unique properties facilitate investigations into GLP-1 signaling pathways and therapeutic strategies for metabolic diseases. -
GLP-1R PAM
V-0219 hydrochloride is a positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). This compound has demonstrated oral bioactivity and is pertinent in the study of obesity-associated diabetes. Its ability to enhance GLP-1R signaling makes it a valuable tool for research into metabolic disorders and therapeutic interventions targeting glucose homeostasis. -
GLP1R Agonist
DD202-114 is a selective agonist of the glucagon-like peptide-1 receptor (GLP1R), demonstrating significant potential for therapeutic applications in type 2 diabetes mellitus and obesity. This compound promotes cAMP accumulation, which is crucial for insulin secretion and glucose homeostasis. DD202-114 also exhibits inhibition of the hERG channel with an IC50 of 15.9 μM and demonstrates strong CYP2C8 inhibition with an IC50 of 0.22 μM. Additionally, it effectively reduces blood glucose levels and food intake, making it a valuable tool for research in metabolic disorders. -
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist 10 is a potent agonist of the glucagon-like peptide-1 (GLP-1) receptor. It has demonstrated the ability to inhibit food intake and reduce glucose excursions in mice, making it a valuable tool for investigating metabolic disorders. This compound is particularly relevant for research applications focused on type 2 diabetes (T2DM) and obesity, providing insights into potential therapeutic strategies for these conditions. -
GLP-1R Agonist Isomer
(1R)-GLP-1 receptor agonist 12 is an isomer targeting the GLP-1 receptor (GLP-1R). It exhibits significant agonistic activity, which can stimulate insulin secretion and enhance β-cell function. This compound is particularly relevant in diabetes research and the study of metabolic disorders, making it a valuable tool for exploring therapeutic strategies in glucose homeostasis and appetite regulation. -
GLP-1R Agonist
GLP-1R agonist 12 is a selective agonist for glucagon-like peptide-1 receptors (GLP-1R), which are integral to glucose metabolism and insulin secretion. This compound promotes insulin release and inhibits glucagon secretion, making it a valuable tool in diabetes research. Its activity may aid in the exploration of therapeutic strategies for metabolic disorders and related conditions. -
GLP Receptor Agonist
Bofanglutide is an analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist, exhibiting an EC50 of 0.677 nM. This compound demonstrates significant efficacy in ameliorating type 2 diabetes by enhancing insulin secretion, suppressing glucagon release, and promoting β-cell proliferation. Bofanglutide is a valuable tool for diabetes research and therapeutic development targeting metabolic disorders.
